MIMEDX to Participate at Upcoming Investor Conferences

Rhea-AI Summary

MIMEDX Group, a leader in regenerative medicine utilizing amniotic tissue, announced that CEO Timothy R. Wright and CFO Peter M. Carlson will participate in two upcoming virtual investor conferences. The first event is the Bank of America Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:45 PM ET, and the second is the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, 2021, at 10:00 AM ET. Interested investors can access the webcasts through the company’s website and contact their representatives for meetings.

MARIETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will be participating in the following virtual investor conferences:

• Bank of America Securities 2021 Virtual Health Care Conference
  Presentation: Thursday, May 13, 2021 at 2:45 PM ET
  Webcast: Click here to access

• Canaccord Genuity Virtual Musculoskeletal Conference
  Fireside Chat: Thursday, May 20, 2021 at 10:00 AM ET
  Webcast: Click here to access

Institutional investors interested in meeting with management may contact their respective Bank of America or Canaccord Genuity representative.

A live webcast of both presentations will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the links above. A replay will be available on the Company’s website following the event.

About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION^® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.MIMEDX.com.

Contacts:
Investors
Jack Howarth
404-360-5681
investorrelations@MIMEDX.com

 

FAQ

What investor conferences is MIMEDX participating in May 2021?

MIMEDX will participate in the Bank of America Securities Virtual Health Care Conference on May 13, 2021, and the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, 2021.

What is the date and time of MIMEDX's presentation at the Bank of America Securities Conference?

MIMEDX's presentation at the Bank of America Securities Conference is on May 13, 2021, at 2:45 PM ET.

When will the Canaccord Genuity Virtual Musculoskeletal Conference take place?

The Canaccord Genuity Virtual Musculoskeletal Conference will take place on May 20, 2021, at 10:00 AM ET.

How can investors access the webcasts for MIMEDX's conference presentations?

Investors can access the webcasts for MIMEDX's conference presentations through the Events page on the company's website.

What is the primary focus of MIMEDX's business?

MIMEDX focuses on utilizing amniotic tissue for regenerative medicine, particularly for non-healing wounds and musculoskeletal conditions.